140 related articles for article (PubMed ID: 17004270)
1. Progress in type II dehydroquinase inhibitors: from concept to practice.
González-Bello C; Castedo L
Med Res Rev; 2007 Mar; 27(2):177-208. PubMed ID: 17004270
[TBL] [Abstract][Full Text] [Related]
2. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
3. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
Robinson DA; Stewart KA; Price NC; Chalk PA; Coggins JR; Lapthorn AJ
J Med Chem; 2006 Feb; 49(4):1282-90. PubMed ID: 16480265
[TBL] [Abstract][Full Text] [Related]
5. Rational design of new bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.
Prazeres VF; Tizón L; Otero JM; Guardado-Calvo P; Llamas-Saiz AL; van Raaij MJ; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2010 Jan; 53(1):191-200. PubMed ID: 19911771
[TBL] [Abstract][Full Text] [Related]
7. Competitive inhibitors of Helicobacter pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies.
Sánchez-Sixto C; Prazeres VF; Castedo L; Suh SW; Lamb H; Hawkins AR; Cañada FJ; Jiménez-Barbero J; González-Bello C
ChemMedChem; 2008 May; 3(5):756-70. PubMed ID: 18200648
[TBL] [Abstract][Full Text] [Related]
8. Understanding the key factors that control the inhibition of type II dehydroquinase by (2R)-2-benzyl-3-dehydroquinic acids.
Peón A; Otero JM; Tizón L; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Gago F; Castedo L; González-Bello C
ChemMedChem; 2010 Oct; 5(10):1726-33. PubMed ID: 20815012
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase.
Sánchez-Sixto C; Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2005 Jul; 48(15):4871-81. PubMed ID: 16033267
[TBL] [Abstract][Full Text] [Related]
10. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
[TBL] [Abstract][Full Text] [Related]
11. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism.
Toscano MD; Payne RJ; Chiba A; Kerbarh O; Abell C
ChemMedChem; 2007 Jan; 2(1):101-12. PubMed ID: 17068841
[TBL] [Abstract][Full Text] [Related]
12. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Comparative binding energy COMBINE analysis for understanding the binding determinants of type II dehydroquinase inhibitors.
Peón A; Coderch C; Gago F; González-Bello C
ChemMedChem; 2013 May; 8(5):740-7. PubMed ID: 23450741
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach.
Schmidt MF; Korb O; Howard NI; Dias MV; Blundell TL; Abell C
ChemMedChem; 2013 Jan; 8(1):54-8. PubMed ID: 23169689
[TBL] [Abstract][Full Text] [Related]
16. The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction.
Gourley DG; Shrive AK; Polikarpov I; Krell T; Coggins JR; Hawkins AR; Isaacs NW; Sawyer L
Nat Struct Biol; 1999 Jun; 6(6):521-5. PubMed ID: 10360352
[TBL] [Abstract][Full Text] [Related]
17. 2-substituted-3-dehydroquinic acids as potent competitive inhibitors of type II dehydroquinase.
Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2009 Dec; 4(12):1980-4. PubMed ID: 19856378
[No Abstract] [Full Text] [Related]
18. Inhibitors of types I and II dehydroquinase.
Le Sann C; Gower MA; Abell AD
Mini Rev Med Chem; 2004 Sep; 4(7):747-56. PubMed ID: 15379642
[TBL] [Abstract][Full Text] [Related]
19. Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis.
Howard NI; Dias MV; Peyrot F; Chen L; Schmidt MF; Blundell TL; Abell C
ChemMedChem; 2015 Jan; 10(1):116-33. PubMed ID: 25234229
[TBL] [Abstract][Full Text] [Related]
20. Parallel solid-phase synthesis and evaluation of inhibitors of Streptomyces coelicolor type II dehydroquinase.
González-Bello C; Lence E; Toscano MD; Castedo L; Coggins JR; Abell C
J Med Chem; 2003 Dec; 46(26):5735-44. PubMed ID: 14667226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]